Strategic Signals Weekly: March 22 – March 29, 2026
March 29, 2026
Werewolf Therapeutics, Inc. strategic alternatives announcement. 16 signals this week: 1 strategic, 15 financing.
Independent Biotech Intelligence
Primary source data for business development, investors, and strategy teams. Trials, filings, patents, and markets - linked and traceable.
About RxDataLab
Research and data tools for the business of biotech
RxDataLab tracks clinical programs, regulatory filings, and market activity for the biotech industry. We build tools for business development teams, investors, and strategy groups who need reliable primary source data. We also publish original analysis from the same data.
Learn more →What's in the Platform
Primary-source data on the business of biotech. Clinical trials, regulatory filings, biotech hedge fund positioning, and insider trading. Updated daily.
Clinical Trial Tracker
Pipeline changes, trial status updates, and competitive landscape mapping across 450K+ trials.
BioHedge
Hedge fund positioning in biotech stocks, updated daily based on schedule 13 filings.
Strategic Signals
Deal activity, partnership filings, and business development signals directly from SEC filings.
Insider Activity
Executive and director trades filed with the SEC, linked to company pipelines.
Financial Context
10-Q Disclosures — select overlays to view events in context
Financial history for
Solid Biosciences Inc.
(SLDB)
— RxDataLab Platform
Overlay:
|
|
Cash
R&D
G&A
◆ = annual (10-K)
Events in View
Want to explore more companies? We cover 500+ — filings, trials, insider trades, and institutional moves, all in one view.
Signup →Research & Resources
Recent Analysis
View all →BioHedge Weekly: March 22 – March 29, 2026
March 29, 2026
Baker Brothers Advisors increased Celcuity Inc. stake to 20.0% (up 1.1pp). 5 filings this week, all activist.
Baker Brothers Renewed Their Acadia Exit Infrastructure
March 24, 2026
Baker Bros filed Schedule 13D Amendment 17 on Acadia showing a renegotiated registration rights agreement allowing block trades. We pulled 14 years of Baker's 13D filing history to see what this could mean.
RxDataLab Research Notes
Primary-source analysis of biotech companies: clinical trials, SEC filings, and hedge fund positioning. Get notified when we publish. No fixed schedule, no filler.
Traceable data for BD, investors, and strategy teams
RxDataLab links regulatory filings to clinical programs and markets, giving you the full picture of who’s filing, what trials they’re running, and how everything connects. Clinical trial records, SEC filings, patent data, and market feeds from primary sources. Every data point traces back to the original filing.
Or email directly at
[email protected]